基于成纤维细胞的心脏重编程在心脏病治疗中的研究进展。

IF 5.4 3区医学 Q2 CELL BIOLOGY

Inflammation Research Pub Date : 2025-08-25 DOI:10.1007/s00011-025-02079-4

Yuanyuan Jin, Yuchang Liu, Ao Ge, Yang Yu, Ying Wan, Chunhong Li, Chunxiang Zhang

{"title":"基于成纤维细胞的心脏重编程在心脏病治疗中的研究进展。","authors":"Yuanyuan Jin, Yuchang Liu, Ao Ge, Yang Yu, Ying Wan, Chunhong Li, Chunxiang Zhang","doi":"10.1007/s00011-025-02079-4","DOIUrl":null,"url":null,"abstract":"Background: Due to population aging and a wide range of risk factors, coupled with the limited regenerative capacity of the myocardium, the prevention and treatment of cardiovascular diseases remain challenging.Methods: This review evaluates cardiac reprogramming as an innovative approach to directly convert fibroblasts into functional cardiomyocytes through genetic or pharmacological means. We focus on its application in myocardial infarction, ischemia-reperfusion injury, and heart failure, and discuss strategies for improving reprogramming efficiency and recent advances in nanomaterial-assisted delivery.Results: Cardiac reprogramming shows potential in reducing fibrosis and restoring function, with efficiency improved through novel delivery systems and optimized protocols.Conclusion: This technology represents a promising strategy for cardiac regeneration, future work should focus on optimizing reprogramming protocols and developing clinically viable delivery systems to accelerate therapeutic translation.","PeriodicalId":13550,"journal":{"name":"Inflammation Research","volume":"74 1","pages":"114"},"PeriodicalIF":5.4000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in fibroblast-based cardiac reprogramming in the treatment of heart disease.\",\"authors\":\"Yuanyuan Jin, Yuchang Liu, Ao Ge, Yang Yu, Ying Wan, Chunhong Li, Chunxiang Zhang\",\"doi\":\"10.1007/s00011-025-02079-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Due to population aging and a wide range of risk factors, coupled with the limited regenerative capacity of the myocardium, the prevention and treatment of cardiovascular diseases remain challenging.Methods: This review evaluates cardiac reprogramming as an innovative approach to directly convert fibroblasts into functional cardiomyocytes through genetic or pharmacological means. We focus on its application in myocardial infarction, ischemia-reperfusion injury, and heart failure, and discuss strategies for improving reprogramming efficiency and recent advances in nanomaterial-assisted delivery.Results: Cardiac reprogramming shows potential in reducing fibrosis and restoring function, with efficiency improved through novel delivery systems and optimized protocols.Conclusion: This technology represents a promising strategy for cardiac regeneration, future work should focus on optimizing reprogramming protocols and developing clinically viable delivery systems to accelerate therapeutic translation.\",\"PeriodicalId\":13550,\"journal\":{\"name\":\"Inflammation Research\",\"volume\":\"74 1\",\"pages\":\"114\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammation Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00011-025-02079-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00011-025-02079-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：由于人口老龄化和多种危险因素，加上心肌再生能力有限，心血管疾病的预防和治疗仍然具有挑战性。方法：本综述评价心脏重编程作为一种通过遗传或药理手段直接将成纤维细胞转化为功能性心肌细胞的创新方法。我们关注其在心肌梗死、缺血再灌注损伤和心力衰竭中的应用，并讨论提高重编程效率的策略和纳米材料辅助输送的最新进展。结果：心脏重编程显示出减少纤维化和恢复功能的潜力，通过新的输送系统和优化的方案提高了效率。结论：这种技术代表了一种很有前途的心脏再生策略，未来的工作应该集中在优化重编程方案和开发临床可行的递送系统上，以加速治疗转化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Advances in fibroblast-based cardiac reprogramming in the treatment of heart disease.

Background: Due to population aging and a wide range of risk factors, coupled with the limited regenerative capacity of the myocardium, the prevention and treatment of cardiovascular diseases remain challenging.

Methods: This review evaluates cardiac reprogramming as an innovative approach to directly convert fibroblasts into functional cardiomyocytes through genetic or pharmacological means. We focus on its application in myocardial infarction, ischemia-reperfusion injury, and heart failure, and discuss strategies for improving reprogramming efficiency and recent advances in nanomaterial-assisted delivery.

Results: Cardiac reprogramming shows potential in reducing fibrosis and restoring function, with efficiency improved through novel delivery systems and optimized protocols.

Conclusion: This technology represents a promising strategy for cardiac regeneration, future work should focus on optimizing reprogramming protocols and developing clinically viable delivery systems to accelerate therapeutic translation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Inflammation Research 医学-免疫学

CiteScore

9.90

自引率

1.50%

发文量

134

审稿时长

3-8 weeks

期刊介绍： Inflammation Research (IR) publishes peer-reviewed papers on all aspects of inflammation and related fields including histopathology, immunological mechanisms, gene expression, mediators, experimental models, clinical investigations and the effect of drugs. Related fields are broadly defined and include for instance, allergy and asthma, shock, pain, joint damage, skin disease as well as clinical trials of relevant drugs.